The company, which recently made Station F’s Future 40 list, offers a proprietary AI-driven platform that significantly enhances the efficiency of teams producing medical documents. It will use the funding to further enhance its product and hire top talent.

Bringing a medical product to market is a costly, complex, and lengthy process. Beyond the clinical development of a new product, each phase, from preclinical research to clinical trials and post-market surveillance, requires extensive and stringent medical documentation crafted by researchers, regulatory- and medical affairs professionals, and market access experts. These medical writers ensure that all documentation related to new or existing products, which can be thousands of pages long, are clear, precise, and compliant with stringent regulatory standards.

Medical writing plays a crucial role in bringing a product to market, but this is a labour-intensive and highly manual profession with low software penetration that is already suffering from workforce shortages. Over the past 10 years, total global spending on pharmaceutical R&D has doubled and as AI is expected to continue accelerating the pace in drug discovery there is a clear need of finding a solution that can speed up medical writing processes.

Biolevate’s proprietary AI driven-platform ELISE is designed to support medical writers by optimising the creation and management of research and compliance documents, leveraging Natural Language Processing (NLP) and Computer Vision and Graph Neural Networks (GNN).

ELISE offers real-time collaborative writing that meets rigorous regulatory standards, with instant suggestions and edits to text, compliance-, and literature review assistance, and effectively works as an assistant to anyone writing medical documents.

Users can interact with the platform to produce content that reflects the latest research in the field and perform automatic validation of regulatory requirements on hundreds of relevant documents at an unprecedented speed. It can also trigger complex analysis on large sets of extracted data to help with forecasting, to support with risk assessments, and to detect anomalies.

Biolevate’s AI technology complements and assists the research and development process, supporting human innovation in driving scientific breakthroughs forward.

Joël Belafa, Co-Founder and CEO at Biolevate commented: “Artificial intelligence has immense potential, and we established Biolevate with a clear mission of using AI to accelerate the development of new therapies, ensuring patients receive life-saving treatments faster. With our platform, medical writing can be accomplished at a much faster rate while ensuring accuracy of information at every stage of drug discovery and development – ultimately elevating the standard of healthcare”

Julien Hobeika, Partner at EQT Ventures, added: “There’s a significant opportunity in making medical writing more efficient using AI, and the team at Biolevate offers an impressive solution to transform medical documentation processes into a seamless and effective procedure that supports innovation and drives scientific breakthroughs benefiting society. At EQT Ventures, we support generation-defining companies that can convert their vision into global successes – and Joël and the team are just getting started: In the long run, their platform can augment any scientist, working with any type of materials.”

For more startup news, check out the other articles on the website, and subscribe to the magazine for free. Listen to The Cereal Entrepreneur podcast for more interviews with entrepreneurs and big-hitters in the startup ecosystem.